The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients
Abstract
Purpose: The epidermal growth factor receptor (EGFR) is overexpressed in ∼50% to 60% of glioblastoma multiforme tumors, and the most common EGFR mutant, EGFRvIII, is expressed in 24% to 67% of cases. We sought to determine whether glioblastoma multiforme expression of either overexpressed wild-type EGFR or the mutant EGFRvIII is an independent predictor of overall patient survival. Experimental Design: Glioblastoma multiforme patients (n = 196) underwent a ≥95% volumetric tumor resection followed by conformal radiation. Their EGFR and EGFRvIII status was determined by immunohistochemistry and survival analyses were done. Results: In our study of glioblastoma multiforme patients, 46% (n = 91) failed to express EGFR, 54% (n = 105) had overexpression of the wild-type EGFR, and 31% (n = 61) also expressed the EGFRvIII. Patients within groups expressing the EGFR, EGFRvIII, or lacking EGFR expression did not differ in age, sex, Karnofsky performance scale score, extent of tumor resection, or radiation. The median overall survival times for patients with tumors having EGFR expression absent, overexpressed only, or mutant (EGFRvIII) were 0.96, 0.98, and 1.07 years, respectively. However, for patients surviving ≥1 year, these values were 2.03, 2.02, and 1.21 years (P < 0.0001; log-rank test comparing EGFRvIII with all others). This effect remained significant in the multivariate analysis after adjustment for all other cofactors including age and Karnofsky performance scale score (rate ratio 4.34; 95% confidence interval, 2.21-8.51). Conclusions: Neither the overexpressed wild-type EGFR nor EGFRvIII was an independent predictor of median overall survival in this selected cohort of patients who underwent extensive tumor resection. However, in patients surviving ≥1 year, the expression of EGFRvIII was an independent negative prognostic indicator.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
Lacroix, M., Abi-Said, D., Fourney, D. R., Gokaslan, Z. L., Shi, W., DeMonte, F., Lang, F. F., McCutcheon, I. E., Hassenbusch, S. J., Holland, E., et al. (2001) · Journal of Neurosurgery · doi:10.3171/jns.2001.95.2.0190 · Cited by 3,091
Self-citationCurran, W. J., Scott, C. B., Horton, J., Nelson, J. S., Weinstein, A. S., Fischbach, A. J., Chang, C. H., Rotman, M., Asbell, S. O., Krisch, R. E., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.9.704 · Cited by 1,310
Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme.
Shinojima, N., Tada, K., Shiraishi, S., Kamiryo, T., Kochi, M., Nakamura, H., Makino, K., Saya, H., Hirano, H., Kuratsu, J., et al. (2003) · PubMed · Cited by 663
Ekstrand, A. J., James, C. D., Cavenee, W. K., Seliger, B., Pettersson, R. F., & Collins, V. P. (1991) · PubMed · Cited by 630
Smith, J. S., Tachibana, I., Passe, S. M., Huntley, B. K., Borell, T. J., Iturria, N., O'Fallon, J. R., Schaefer, P. L., Scheithauer, B. W., James, C. D., et al. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.16.1246 · Cited by 630
Davis, F. G., Freels, S., Grutsch, J., Barlas, S., & Brem, S. (1998) · Journal of Neurosurgery · doi:10.3171/jns.1998.88.1.0001 · Cited by 482
Cited by
Phillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., Misra, A., Nigro, J. M., Colman, H., Soroceanu, L., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.02.019 · Cited by 3,143
Self-citationO’Rourke, D. M., Nasrallah, M. P., Desai, A., Melenhorst, J. J., Mansfield, K., Morrissette, J. J. D., Martinez-Lage, M., Brem, S., Maloney, E., Shen, A., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa0984 · Cited by 1,803
Sampson, J. H., Heimberger, A. B., Archer, G. E., Aldape, K. D., Friedman, A. H., Friedman, H. S., Gilbert, M. R., Herndon, J. E., McLendon, R. E., Mitchell, D. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.6963 · Cited by 815
Self-citationGlioma Subclassifications and Their Clinical Significance
Chen, R., Smith-Cohn, M., Cohen, A. L., & Colman, H. (2017) · Neurotherapeutics · doi:10.1007/s13311-017-0519-x · Cited by 812
Glioblastoma: pathology, molecular mechanisms and markers
Aldape, K., Zadeh, G., Mansouri, S., Reifenberger, G., & von Deimling, A. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1432-1 · Cited by 735
Self-citation
Metadata
- Authors
- Heimberger, A. B., Hlatky, R., Suki, D., Yang, D., Weinberg, J., Gilbert, M., Sawaya, R., & Aldape, K.
- Venue
- Clinical Cancer Research
- Published
- 2005-02-15
- Volume
- 11
- Issue
- 4
- Pages
- 1462-1466
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2010956784
- Cited by
- 516
- References
- 22
- FWCI
- 7.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-04-1737
- The paper
- Heimberger, A. B., Hlatky, R., Suki, D., Yang, D., Weinberg, J., Gilbert, M., Sawaya, R., & Aldape, K. (2005). Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-04-1737
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.